uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Tiensuu Janson, Eva
Alternative names
Publications (10 of 112) Show all publications
Ramage, J. K., Valle, J., Nieveen van Dijkum, E. J., Sundin, A., Pascher, A., Couvelard, A. & Kloeppel, G. (2019). Colorectal Neuroendocrine Neoplasms - areas of unmet need. Neuroendocrinology, 108(1), 45-53
Open this publication in new window or tab >>Colorectal Neuroendocrine Neoplasms - areas of unmet need
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 45-53Article in journal (Refereed) Published
Abstract [en]

The subject of colorectal neuroendocrine neoplasms (NENs), subdivided into well-differentiated NENs, termed neuroendocrine tumours (NETs; grade (G) 1 and 2), and poorly differentiated NENs, termed neuroendocrine carcinomas (NECs; G3) according to the 2010 World Health Organisation (WHO) classification, has arguably not had as much attention or study as NENs occurring in other sites. Colorectal NETs and NECs are however easier to study than many others since they are usually not difficult to remove and are increasingly detected because of intensified colorectal cancer screening and surveillance programmes. Colorectal NETs and NECs show site-specific heterogeneity with variable behaviour and different therapeutic options; these various aspects provide unique challenges. Because of bowel cancer screening programmes, colorectal NENs, like conventional adenocarcinomas, may be diagnosed at a stage that is associated with improved survival. In this article we intend to describe and define areas of unmet needs relating to the epidemiology, classification, pathology, diagnosis and therapy of colorectal NETs (including NETs G3), colorectal NECs, and finally, mixed adeno-neuroendocrine carcinomas (MANECs) by reviewing and discussing the relevant literature.

Keywords
Carcinoid tumours, Gastroenteropancreatic neuroendocrine tumours, Neuroendocrine tumour, Somatostatin receptor
National Category
Cancer and Oncology Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-362622 (URN)10.1159/000493767 (DOI)000456048400006 ()30219817 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2019-02-11Bibliographically approved
Capdevila, J., Bodei, L., Davies, P., Gorbounova, V., Jensen, R. T., Knigge, U. P., . . . Pavel, M. E. (2019). Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. Neuroendocrinology, 108(1), 18-25
Open this publication in new window or tab >>Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 18-25Article in journal (Refereed) Published
Abstract [en]

Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.

Keywords
Biomarkers, Imaging, Metastasis, Neuroendocrine neoplasms, Therapy, Unmet medical needs
National Category
Endocrinology and Diabetes Psychiatry
Identifiers
urn:nbn:se:uu:diva-375573 (URN)10.1159/000493319 (DOI)000456048400003 ()30153686 (PubMedID)
Note

ENETS 2016 Munich Advisory Board Participants, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Baudin, E., Hayes, A. R., Scoazec, J.-Y., Filosso, P. L., Lim, E., Kaltsas, G., . . . Caplin, M. E. (2019). Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. Neuroendocrinology, 108(1), 7-17
Open this publication in new window or tab >>Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 7-17Article in journal (Refereed) Published
Abstract [en]

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

Keywords
Bronchial carcinoid tumours, NET, Neuroendocrine neoplasms, Pulmonary carcinoids
National Category
Endocrinology and Diabetes Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-375567 (URN)10.1159/000493980 (DOI)000456048400002 ()30248673 (PubMedID)
Note

ENETS 2016 Munich Advisory Board Participants (UU authors): Jenny Falkerby; Anders Sundin; Eva Tiensuu Janson & Staffan Welin

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Toumpanakis, C., Fazio, N., Tiensuu Janson, E., Hörsch, D., Pascher, A., Reed, N., . . . Scoazec, J.-Y. (2019). Unmet Needs in Appendiceal Neuroendocrine Neoplasms. Neuroendocrinology, 108(1), 37-44
Open this publication in new window or tab >>Unmet Needs in Appendiceal Neuroendocrine Neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 37-44Article in journal (Refereed) Published
Abstract [en]

Appendiceal neuroendocrine neoplasms (ANEN) are mostly discovered coincidentally during appendicectomy and usually have a benign clinical course; thus, appendicectomy alone is considered curative. However, in some cases, a malignant potential is suspected, and therefore additional operations such as completion right hemicolectomy are considered. The existing European Neuroendocrine Tumour Society (ENETS) guidelines provide useful data about epidemiology and prognosis, as well as practical recommendations with regards to the risk factors for a more aggressive disease course and the indications for a secondary operation. However, these guidelines are based on heterogeneous and retrospective studies. Therefore, the evidence does not seem to be robust, and there are still unmet needs in terms of accurate epidemiology and overall prognosis, optimal diagnostic and follow-up strategy, as well as identified risk factors that would indicate a more aggressive surgical approach at the beginning and a more intense follow-up. In this review, we are adopting a critical approach of the ENETS guidelines and published series for ANEN, focusing on the above-noted "grey areas".

Keywords
Appendiceal neuroendocrine neoplasms, Appendicectomy, Appendix, Carcinoids, Right hemicolectomy
National Category
Endocrinology and Diabetes Neurosciences
Identifiers
urn:nbn:se:uu:diva-375571 (URN)10.1159/000493894 (DOI)000456048400005 ()30235454 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Jensen, R. T., Bodei, L., Capdevila, J., Couvelard, A., Falconi, M., Grozinsky-Glasberg, S., . . . Fazio, N. (2019). Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms. Neuroendocrinology, 108(1), 26-36
Open this publication in new window or tab >>Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 26-36Article in journal (Refereed) Published
Abstract [en]

Recently, the European Neuroendocrine Tumor Society (ENETS) held working sessions composed of members of the advisory board and other neuroendocrine neoplasm (NEN) experts to attempt to identify unmet needs in NENs in different locations or with advanced/poorly differentiated NENs. This report briefly summarizes the main proposed areas of unmet needs in patients with functional and nonfunctional pancreatic NENs.

National Category
Endocrinology and Diabetes Neurosciences
Identifiers
urn:nbn:se:uu:diva-362648 (URN)10.1159/000494258 (DOI)000456048400004 ()30282083 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan

Available from: 2018-10-08 Created: 2018-10-08 Last updated: 2019-02-11Bibliographically approved
Sorbye, H., Baudin, E., Borbath, I., Caplin, M., Chen, J., Cwikla, J. B., . . . Garcia-Carbonero, R. (2019). Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology, 108(1), 54-62
Open this publication in new window or tab >>Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Show others...
2019 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 108, no 1, p. 54-62Article in journal (Refereed) Published
Abstract [en]

Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are classified based on morphology and graded based on their proliferation rate as either well-differentiated low-grade (G1 to G2) neuroendocrine tumors (NET) or poorly differentiated high-grade (G3) neuroendocrine carcinomas (NEC). Recently, a new subgroup of well-differentiated high-grade pancreatic tumors (NET G3) has been defined. The GEP NEN G3 group consisting of both NEC and NET G3 has recently been shown to be a quite heterogeneous patient group concerning prognosis and treatment benefit, depending on factors such as the primary tumor site, differentiation, proliferation rate, and molecular alterations. In this review we discuss the existing data on diagnostics, treatment, and biomarkers in this patient group, the unmet needs, and the future perspectives.

Keywords
Neuroendocrine carcinoma, Neuroendocrine neoplasm, Neuroendocrine tumor
National Category
Neurosciences Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-375598 (URN)10.1159/000493318 (DOI)000456048400007 ()30153658 (PubMedID)
Note

ENETS 2016 Munich Advisory Board, Uppsala University: Falkerby, Jenny; Sundin, Anders; Tiensuu Janson, Eva & Welin, Staffan.

Available from: 2019-01-31 Created: 2019-01-31 Last updated: 2019-02-11Bibliographically approved
Dam, G., Grønbæk, H., Sørbye, H., Thiis-Evensen, E., Paulsson, B., Sundin, A., . . . Tiensuu Janson, E. (2018). A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors. Paper presented at 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 07-09, 2018, Barcelona, SPAIN. Neuroendocrinology, 106(Supplement: 1), 152-152
Open this publication in new window or tab >>A Prospective Nordic Study on the Use of Chromogranin A for the Prediction of Progression in Patients with Pancreatic and Small Intestinal Neuroendocrine Tumors
Show others...
2018 (English)In: Neuroendocrinology, ISSN 0028-3835, E-ISSN 1423-0194, Vol. 106, no Supplement: 1, p. 152-152Article in journal, Meeting abstract (Other academic) Published
Keywords
gep-net, ct, cga, correlation
National Category
Endocrinology and Diabetes
Identifiers
urn:nbn:se:uu:diva-355840 (URN)10.1159/000487699 (DOI)000427285300150 ()
Conference
15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, MAR 07-09, 2018, Barcelona, SPAIN
Note

Meeting Abstract: F05

Available from: 2018-07-13 Created: 2018-07-13 Last updated: 2018-07-13Bibliographically approved
Daskalakis, K., Karakatsanis, A., Hessman, O., Stuart, H. C., Welin, S., Tiensuu Janson, E., . . . Stålberg, P. (2018). Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.. JAMA Oncology, 4(2), 183-189
Open this publication in new window or tab >>Association of a Prophylactic surgical approach to Stage IV Small Intestinal Neuroendocrine Tumors with Survival.
Show others...
2018 (English)In: JAMA Oncology, ISSN 2374-2437, E-ISSN 2374-2445, Vol. 4, no 2, p. 183-189Article in journal (Refereed) Published
Abstract [en]

Importance: Primary tumor resection and mesenteric lymph node dissection in asymptomatic patients with stage IV Small Intestinal Neuroendocrine Tumors (SI-NETs) is controversial.

Objective:  To determine whether locoregional surgery performed at diagnosis in asymptomatic SI-NETs patients with distant metastases affects overall survival (OS), morbidity and mortality, length of hospital stay (LOS) and re-operation rates.

Design: This investigation was a cohort study of asymptomatic patients with stage IV SI-NET, diagnosed between 1985 and 2015, using the prospective Uppsala database of SI-NETs and the Swedish National Patient Register. Patients included were followed until May 2016 and divided to a first group, which underwent Prophylactic Upfront Surgery within six months from diagnosis Combined with Oncological treatment (PUSCO group) and a second group, which was either treated non-surgically or operated later (Delayed Surgery As Needed Combined with Oncological treatment [DSANCO group]).

Setting: A tertiary referral center with follow-up data from the Swedish National Patient Register.

Participants: We included 363 stage IV SI-NET patients without any abdominal symptoms within 6 months from diagnosis, treated either with PUSCO (n=161) or DSANCO (n=202).

Exposure: PUSCO vs DSANCO.

Main Outcomes and Measures: Overall survival (OS), length of hospital stay (LOS), postoperative morbidity and mortality and re-operation rates measured from baseline. Propensity score match was performed between the two groups.

Results: Two isonumerical groups (n=91) occurred after propensity score matching. There was no difference between groups in OS (PUSCO median 7.9 vs DSANCO 7.6 years; [hazard ratio] HR, 0.98; [95% CI, 0.70-1.37]; log-rank P=.93) and cancer-specific survival (median 7.7 vs 7.6 years, HR, 0.99; [95%CI, 0.71-1.40]; log-rank P=.99). There was no difference in 30-day mortality (0% in both matched groups) or postoperative morbidity (2% vs 1%; P>.99), LOS (median 73 vs 76 days; P=.64), LOS due to local tumor-related symptoms (median 7 vs 11.5 days; P=.81) or incisional hernia repairs (4% in both groups; P>.99).  Patients from the PUSCO group underwent more re-operative procedures (14%) compared to the DSANCO group (3%) due to intestinal obstruction (P< .001).

Conclusion: Prophylactic upfront locoregional surgery confers no survival advantage in asymptomatic stage IV SI-NET patients. Delayed surgery as needed seems to be comparable in all examined outcomes, whilst offering the advantage of less re-operations for intestinal obstruction.  The value of a priori locoregional surgery in the presence of distant metastases is challenged and needs to be elucidated in a randomized controlled study.

 

Keywords
Small Intestinal NETs, prophylactic loco-regional surgery, stage IV
National Category
Surgery
Identifiers
urn:nbn:se:uu:diva-330702 (URN)10.1001/jamaoncol.2017.3326 (DOI)000424778600010 ()29049611 (PubMedID)
Funder
Göran Gustafsson Foundation for Research in Natural Sciences and MedicineSwedish Cancer Society
Available from: 2017-10-21 Created: 2017-10-03 Last updated: 2018-04-16Bibliographically approved
Georgantzi, K., Sköldenberg, E., Stridsberg, M., Kogner, P., Jakobson, Å., Tiensuu Janson, E. & Christofferson, R. H. H. (2018). Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.. Pediatric Hematology & Oncology, 35(2), 156-165
Open this publication in new window or tab >>Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Show others...
2018 (English)In: Pediatric Hematology & Oncology, ISSN 0888-0018, E-ISSN 1521-0669, Vol. 35, no 2, p. 156-165Article in journal (Refereed) Published
Abstract [en]

Chromogranin A (CgA) and neuron specific enolase (NSE) are important markers in adult neuroendocrine tumors (NET). Neuroblastoma (NB) has certain neuroendocrine properties. The aim of this study was to correlate blood concentrations of CgA, chromogranin B (CgB), and NSE to prognostic factors and outcome in children with NB. Blood samples from 92 patients with NB, 12 patients with benign ganglioneuroma (GN), 21 patients with non-NB solid tumors, 10 patients with acute leukemias, and 69 healthy children, were analyzed. CgA concentrations were higher in neonates vs. children older than one month in the control group (p < 0.0001), and in neonates with NB vs. the control group (p < 0.01). CgA and NSE concentrations were higher in patients with stages 3 and 4 disease (p < 0.05 and p < 0.05), in patients having tumors with amplification of MYCN (p < 0.05 and p < 0.001), or chromosome 1 p deletion (p < 0.05 and p < 0.05). NSE correlated to the tumor size at diagnosis (p < 0.001) and to tumor related death (p < 0.01) in NB. CgA and NSE concentrations were elevated in patients with NB and especially in those with advanced disease. Both CgA and NSE correlated to genetic markers, while only NSE correlated to primary tumor size and outcome in NB. We found that CgA and NSE are clinically valuable tumor markers in NB and they merit prospective clinical evaluations as such.

Keywords
Chromogranin A, neuroblastoma, neuron-specific enolase, prognosis, tumor markers
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-360970 (URN)10.1080/08880018.2018.1464087 (DOI)000446356300007 ()29737901 (PubMedID)
Funder
Swedish Childhood Cancer Foundation
Available from: 2018-09-20 Created: 2018-09-20 Last updated: 2018-12-07Bibliographically approved
Grönberg, M., Nilsson, C., Markholm, I., Hedenfalk, I., Blomqvist, C., Holmberg, L., . . . Fjällskog, M.-L. (2018). Ghrelin expression is associated with a favorable outcome in male breast cancer. Scientific Reports, 8, Article ID 13586.
Open this publication in new window or tab >>Ghrelin expression is associated with a favorable outcome in male breast cancer
Show others...
2018 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 8, article id 13586Article in journal (Refereed) Published
Abstract [en]

Ghrelin and obestatin are two gastrointestinal peptides, derived from a common precursor. Expression of both peptides have been found in breast cancer tissue and ghrelin has been associated with breast cancer development. Ghrelin expression is associated with longer survival in women diagnosed with invasive and node negative breast cancer. The clinical implications of the peptide expression in male breast cancer are unclear. The aim of this study was to investigate the role and potential clinical value of ghrelin and obestatin in male breast cancer. A tissue microarray of invasive male breast cancer specimens from 197 patients was immunostained with antibodies versus the two peptides. The expression of the peptides was correlated to previously known prognostic factors in breast cancer and to the outcome. No strong correlations were found between ghrelin or obestatin expression and other known prognostic factors. Only ghrelin expression was statistically significantly correlated to breast cancer-specific survival (HR 0.39, 95% CI 0.18-0.83) in univariate analyses and in multivariate models, adjusted for tumor size and node status (HR 0.38, 95% CI 0.17-0.87). HR for obestatin was 0.38 (95% CI 0.11-1.24). Ghrelin is a potential prognostic factor for breast cancer death in male breast cancer. Patients with tumors expressing ghrelin have a 2.5-fold lower risk for breast cancer death than those lacking ghrelin expression. Drugs targeting ghrelin are currently being investigated in clinical studies treating metabolic or nutritional disorders. Ghrelin should be further evaluated in forthcoming studies as a prognostic marker with the aim to be included in decision algorithms.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-365298 (URN)10.1038/s41598-018-31783-x (DOI)000444278400020 ()30206250 (PubMedID)
Funder
Swedish Cancer Society, CAN 2014/558Swedish Cancer Society, CAN 2011/461The Breast Cancer FoundationErik, Karin och Gösta Selanders Foundation
Available from: 2018-11-13 Created: 2018-11-13 Last updated: 2018-11-13Bibliographically approved
Organisations

Search in DiVA

Show all publications